Aldosterone receptor antagonists: Effective but often forgotten

Circulation

Volumn 121, Issue 7, 2010, Pages 934-939

  Maron, Bradley A ^a   Leopold, Jane A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Heart failure; Hypertension; Obesity; Pharmacokinetics; Pharmacology

Indexed keywords

ALDOSTERONE ANTAGONIST; CLARITHROMYCIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; SPIRONOLACTONE;

ABDOMINAL PAIN; AMENORRHEA; BREAST TENDERNESS; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DYSMENORRHEA; ENZYME SYNTHESIS; ERECTILE DYSFUNCTION; ESSENTIAL HYPERTENSION; FOLLOW UP; GYNECOMASTIA; HEART INFARCTION; HUMAN; HYPERKALEMIA; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT INDICATION;

ALDOSTERONE ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MIDDLE AGED; MYOCARDIAL INFARCTION; RECEPTORS, ALDOSTERONE; RENAL INSUFFICIENCY, CHRONIC; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 77649106201     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.895235     Document Type: Review

References (38)

1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341:709-717.
2. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
3. Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J. 2009;30:469-477.
4. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119: 1977-2016.
5. Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GC. Use of aldosterone antagonists in heart failure. JAMA. 2009;21:1658-1665.
6. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543-551.
7. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689-1697.
8. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med. 2007;13:189-197.
9. Gaddam KK, Verma A, Thompson M, Amin R, Ventura H. Hypertension and cardiac failure in its various forms. Med Clin North Am. 2009;93:665-680.
10. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myo-cardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008;118:1643-1650.
11. Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol. 2008;31:153-158.
12. Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med. 2000;109:307-314.
13. Witham MD, Gillespie ND, Struthers AD. Hy-perkalemia after the publication of RALES. N Engl J Med. 2004;351:2448-2450.
14. Shah KB, Rao K, Sawyer R, Gottlieb SS. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol. 2005;46:845-849.
15. Jorde UP, Vittorio T, Katz SD, Colombo PC, Latif F, Le Jemtel TH. Elevated plasma al-dosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation. 2002;106:1055-1057.
16. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, van Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46:425-431. (Pubitemid 41040281)
17. Beygui F, Montalescot G, Vicaut E, Rouanet S, Van Belle E, Baulac C, Degrandsart A, Dallongeville J. Aldosterone and long-term outcome after myocardial infarction: a substudy of the French nationwide Obser-vatoire sur la Prise en charge hospitaliere, l'Evolution a un an et les caRacteristiques de patients presentant un infArctus du myocarde avec ou sans onde Q (OPERA) study. Am Heart J. 2009;157:680-687.
18. Gheorghiade M, Khan S, Blair JE, Harinstein ME, Krum H, Mukherjee R, Pitt B. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. Am Heart J. 2009;158: 437-443.
19. Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, Marino P, Zardini P. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol. 2002;40:304-310.
20. Boccanelli A, Mureddu GF, Cacciatore G, Clemenza F, Di Lenarda A, Gavazzi A, Porcu M, Latini R, Lucci D, Maggioni AP, Masson S, Vanasia M, de Simone G. Anti-Remodelling Effect of Canrenone in Patients With Mild Chronic Heart Failure (AREA IN-CHF study): final results. Eur J Heart Fail. 2009;11:68-76.
21. Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH. Effect of al-dosterone antagonism on myocardial dysfunction in hypertensive patients with dia-stolic heart failure. Circulation. 2004;110: 558-565.
22. Pratt-Ubunama MN, Nishizaka MK, Boe-defeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest. 2007;131:453-459.
23. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:33-41.
24. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48: 2293-2300.
25. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldoste-ronism among black and white subjects with resistant hypertension. Hypertension. 2002; 40:892-896.
26. Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE. Primary aldosteronism and hypertensive disease. Hypertension. 2003; 42:161-165.
27. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-1248.
28. Karagiannis A, Tziomalos K, Papageorgiou A, Kakafika AI, Pagourelias ED, Anagnostis P, Athyros VG, Mikhailidis DP. Spirono-lactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother. 2008;9:509-515.
29. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925-930.
30. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, Poulter NR. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839-845.
31. Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, Yang Y, Krause SL, Workman D, Saunders E. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol. 2003;41:1148-1155.
32. Savoia C, Touyz RM, Amiri F, Schiffrin EL. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension. 2008;51:432-439.
33. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, Sechi LA. Long-term cardiac effects of adrenal-ectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension. 2007;50:911-918.
34. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hyper tension and left ventricular hypertrophy: the 4E-Left Ventricular Hypertrophy Study. Circulation. 2003;108:1831-1838.
35. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, Catena C. Long-term renal outcomes in patients with primary aldosteronism. JAMA. 2006;295: 2638-2645. (Pubitemid 43882339)
36. Fox CS, Larson MG, Hwang SJ, Leip EP, Rifai N, Levy D, Benjamin EJ, Murabito JM, Meigs JB, Vasan RS. Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample. Kidney Int. 2006;69:2064-2069.
37. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4:542-551.
38. Sarafidis PA, Bakris GL. Resistant hypertension. J Am Coll Cardiol. 2008;52: 1749-1757.